GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aprinoia Therapeutics Inc (NAS:APRI) » Definitions » Operating Margin %
中文

Aprinoia Therapeutics (Aprinoia Therapeutics) Operating Margin % : -74.57% (As of Jun. 2023)


View and export this data going back to 2050. Start your Free Trial

Aprinoia Therapeutics Operating Margin % Definition

Operating Margin % is calculated as Operating Income divided by its Revenue. Aprinoia Therapeutics's Operating Income for the six months ended in Jun. 2023 was $-6.74 Mil. Aprinoia Therapeutics's Revenue for the six months ended in Jun. 2023 was $9.03 Mil. Therefore, Aprinoia Therapeutics's Operating Margin % for the quarter that ended in Jun. 2023 was -74.57%.

The historical rank and industry rank for Aprinoia Therapeutics's Operating Margin % or its related term are showing as below:


APRI's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -177.8
* Ranked among companies with meaningful Operating Margin % only.

Aprinoia Therapeutics's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Aprinoia Therapeutics's Operating Income for the six months ended in Jun. 2023 was $-6.74 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2023 was $-21.16 Mil.


Aprinoia Therapeutics Operating Margin % Historical Data

The historical data trend for Aprinoia Therapeutics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aprinoia Therapeutics Operating Margin % Chart

Aprinoia Therapeutics Annual Data
Trend Dec21 Dec22
Operating Margin %
-4,344.91 -7,173.60

Aprinoia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23
Operating Margin % - -4,692.54 -14,566.67 -74.57

Competitive Comparison of Aprinoia Therapeutics's Operating Margin %

For the Biotechnology subindustry, Aprinoia Therapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aprinoia Therapeutics Operating Margin % Distribution

For the Biotechnology industry and Healthcare sector, Aprinoia Therapeutics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Aprinoia Therapeutics's Operating Margin % falls into.



Aprinoia Therapeutics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Aprinoia Therapeutics's Operating Margin % for the fiscal year that ended in Dec. 2022 is calculated as

Operating Margin %=Operating Income (A: Dec. 2022 ) / Revenue (A: Dec. 2022 )
=-28.264 / 0.394
=-7,173.60 %

Aprinoia Therapeutics's Operating Margin % for the quarter that ended in Jun. 2023 is calculated as

Operating Margin %=Operating Income (Q: Jun. 2023 ) / Revenue (Q: Jun. 2023 )
=-6.737 / 9.034
=-74.57 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aprinoia Therapeutics  (NAS:APRI) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Aprinoia Therapeutics Operating Margin % Related Terms

Thank you for viewing the detailed overview of Aprinoia Therapeutics's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Aprinoia Therapeutics (Aprinoia Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.

Aprinoia Therapeutics (Aprinoia Therapeutics) Headlines

No Headlines